FOXO4-DRI
Clinical Status
Preclinical — extensive animal research, Phase 1 trials planned.
Mechanism of Action
Interferes with FOXO4-p53 binding in senescent cells. Releases p53 to trigger apoptosis specifically in senescent cells while sparing healthy cells.
Dosing Defaults
Dose
2-10 mg every other day
Frequency
3 doses every other day, 1-3 cycles/year
Administration
Subcutaneous injection
Timing
Per protocol
Food
with or without
Duration
1 cycle = 3 doses over 5-6 days
Dose range: 2-25 mg per injection
Short cycling prevents over-clearance of beneficial senescent cells.
Side Effects
- •Injection site reactions
- •Fatigue
- •Muscle soreness
- •Nausea
- •Limited human safety data
Contraindications & Warnings
- •Not medical advice
- •Could affect beneficial senescent cells
Compare
Compare FOXO4-DRI with another peptide side-by-side.
Ad
Related Anti-Aging & Longevity Peptides
This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.